Trevi Therapeutics, Inc. TRVI Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueNewIssues.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment?
- Trevi Therapeutics, Inc. (TRVI) reported issuance of common stock in connection with the spin-off and reclassification of net parent investment of $20K in Q4 2025.
- How has Trevi Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment changed year-over-year?
- Trevi Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment decreased by 99.8% year-over-year, from $11.69M to $20K.
- What does issuance of common stock in connection with the spin-off and reclassification of net parent investment mean?
- The total proceeds received from the issuance of new common stock to the public or private investors. This represents a primary source of external financing for clinical-stage companies to fund research and development activities. It highlights the company's ability to access capital markets to support its operational pipeline.